

Kontaktallergie Risiko durch topische Medikamente

PHARMACOEPIDEMOLOGY AND DRUG SAFETY 2008; 17: 813–821

Published online 26 March 2008 in Wiley InterScience (www.interscience.wiley.com) DOI: 10.1002/pds.1588

ORIGINAL REPORT

Allergic contact dermatitis to topical drugs— epidemiological risk assessment[†]

C. A. Menezes de Pádua PhD¹, A. Schnuch MD², K. Nink MPH³,
A. Pfahlberg PhD¹ and W. Uter MD^{1*}

Kontaktallergie Risiko durch topische Medikamente

FREQUENCY VERSUS RISK

ANTIBIOTICS

	IVDK	CE-DUR	DDDs	RI (relative incidence)
Topical drugs	Clinical data % CS	CS cases	Prescriptions (millions DDDs) ¹	RI (cases/100,000 DDD-year) (95%CI)
Bacitracin	1.5	1701	10.2	16.7 (8.1-25.3)
Gentamicin	2.9	3245	11.2	29.0 (18.2-39.8)
Framycetin	4.1	4619	5.8	86.2 (60.4-112.0)
Oxytetracycline	0.1	146	9.1	1.6 (0.0-4.5)
Fusidic acid	1.1	1269	17.1	7.4 (3.0-11.8)
Polymyxin B	1.0	1076	13.2	8.2 (2.6-13.8)
Chloramphenicol	3.3	4040	17.3	23.3 (15.5-31.1)

Kontaktallergie Risiko durch topische Medikamente

FREQUENCY VERSUS RISK

ANTIMYCOTICS

Topical drugs	IVDK Clinical data % CS	CE-DUR CS cases	DDDs Prescriptions (millions DDDs) ¹	RI (relative incidence) RI (cases/100,000 DDD-year) (95%CI)
Nystatin	0.4	287	>30.7	0.9 (0.0-2.2)
Clotrimazol	0.5	574	>69.8	0.8 (0.1-1.5)

Kontaktallergie Risiko durch topische Medikamente

FREQUENCY VERSUS RISK


LOCAL ANAESTHETICS

Topical drugs


	IVDK	CE-DUR	DDDs	RI (relative incidence)	
	Clinical data % CS	CS cases	Prescriptions (millions DDDs) ¹	RI (cases/100,000 DDD-year) (95%CI)	
Lidocaine	1.1	256	≥16.6	1.5	(0.0-3.8)
Procaine	1.6	391	≥12.3	3.2	(0.0-6.4)
Tetracaine	0.9	497	0.7	107.8	(60.4-112.0)
Polidocanol	1.9	3835	≥52.1	3.2	(1.5-4.7)

Kontaktallergie Risiko durch topische Medikamente

Kontaktallergie: Struktur-Wirkungsbeziehung




Benzocaine
RI: 413.9



Tetracaine
RI:107.8

Ester-Typ



Lidocaine
RI: 1.5

Amid-Typ

Kontaktallergie Risiko durch topische Medikamente

FREQUENCY VERSUS RISK

OPHTHALMICS

Topical drugs	IVDK Clinical data % CS	CE-DUR CS cases	DDDs Prescriptions (millions DDDs) ¹	RI (relative incidence) RI (cases/100,000 DDD-year) (95%CI)	
Atropin	0.3	155	5.7	2.7 (0-07.4)	
Phenylephrin	1.9	891	≥4.1	21.6 (6.2-37.0)	
Pilocarpin	0.4	169	59.6	0.3 (0.0-0.7)	
Kanamycin	2.9	1336	15.4	8.7 (3.7-13.7)	
Gentamicin	3.5	2077	43.3	4.8	RI: 29 als Salbe
Polymyxin B	0.7	314	22.7	1.4 (0.0-3.1)	
Chloramphenicol	0.9	436	10.4	4.0	RI: 23.3 als Salbe

Kontaktallergie Risiko durch topische Medikamente

FREQUENCY VERSUS RISK

CORTICOSTEROIDS	IVDK	CE-DUR	DDDs	RI (relative incidence)	
Topical drugs	Clinical data % CS	CS cases	Prescriptions (millions DDDs) ¹	RI (cases/100,000 DDD-year) (95%CI)	
Amcinonide	1.6	1155	4.9	23.6	(8.9-38.3)
Hydrocortisone	0.3	228	≥24.1	0.9	(0.0-2.2)
Triamcinolone acetoni	0.5	392	27.5	1.4	(0.0-2.9)
Clobetasol 17-prop	0.4	299	21.0	1.4	(0.0-3.2)
Hydrocortisone-17 but	1.5	1062	10.0	10.7	(3.7-17.7)
Betamethasone-17_val	0.5	335	60.4	0.6	(0.0-1.2)
Budesonide	2.6	2082	4.8	43.2	(24.4-62.0)
Prednisolone	0.4	320	59,9	0.5	(0.0-1.1)
Dexamethasone-21-Ph	0.4	288	86.1	0.3	(0.0-0.7)